(AMPH) Amphastar P - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032
AMPH: Injectables, Inhalation, Nasal, Sprays, Vaccines, Medicines
Amphastar Pharmaceuticals (NASDAQ:AMPH) is a bio-pharmaceutical company with a focus on injectable, inhalation, and intranasal products. Operating primarily in the U.S., China, and France, they offer a mix of generic and proprietary drugs. Their product portfolio includes BAQSIMI, a nasal spray for severe hypoglycemia, and Primatene Mist, an OTC epinephrine inhaler for mild asthma. Enoxaparin, used to prevent deep vein thrombosis, is another key product, alongside Rextovy and Naloxone for opioid overdose treatment. They also provide Glucagon emergency kits and Cortrosyn for diagnostic purposes.
The companys range extends to anesthetic and emergency products such as Amphadase, Epinephrine injections, and Lidocaine jelly. They distribute insulin APIs, a significant part of their business. Amphastar is actively developing generics, biosimilars, and an intranasal epinephrine spray, showcasing their commitment to innovation and pipeline growth.
Financially, Amphastar has a market cap of around $1.5 billion, with a P/E ratio of 10.55, indicating a reasonable valuation. Their P/B ratio of 2.10 and P/S of 2.06 are key metrics for investors assessing the companys financial health and market position.
Additional Sources for AMPH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMPH Stock Overview
Market Cap in USD | 1,349m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2014-06-25 |
AMPH Stock Ratings
Growth 5y | 48.2% |
Fundamental | 79.1% |
Dividend | 0.0% |
Rel. Strength Industry | -39.6 |
Analysts | 4/5 |
Fair Price Momentum | 23.45 USD |
Fair Price DCF | 83.58 USD |
AMPH Dividends
No Dividends PaidAMPH Growth Ratios
Growth Correlation 3m | -94.9% |
Growth Correlation 12m | -25.5% |
Growth Correlation 5y | 83.9% |
CAGR 5y | 15.02% |
CAGR/Max DD 5y | 0.25 |
Sharpe Ratio 12m | -1.33 |
Alpha | -46.65 |
Beta | 0.67 |
Volatility | 46.64% |
Current Volume | 467.6k |
Average Volume 20d | 562.9k |
As of March 14, 2025, the stock is trading at USD 26.24 with a total of 467,567 shares traded.
Over the past week, the price has changed by -7.34%, over one month by -17.33%, over three months by -37.88% and over the past year by -39.75%.
Yes, based on ValueRay Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (March 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 79.08 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMPH as of March 2025 is 23.45. This means that AMPH is currently overvalued and has a potential downside of -10.63%.
Amphastar P has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy AMPH.
- Strong Buy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 25.5 in March 2026. The stock is currently trading at 26.24. This means that the stock has a potential downside of -2.74%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 39.8 | 51.7% |
Analysts Target Price | 56.4 | 114.9% |
ValueRay Target Price | 25.5 | -2.7% |